FORM 4 [X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Frazier Life Sciences Public Fund, L.P.
2. Issuer Name and Ticker or Trading Symbol

Viridian Therapeutics, Inc.DE [ VRDN ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    __X__ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

C/O FRAZIER HEALTHCARE PARTNERS, 601 UNION STREET, SUITE 3200
3. Date of Earliest Transaction (MM/DD/YYYY)

9/23/2021
(Street)

SEATTLE, WA 98101
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 9/23/2021  P  200000 A$11.00 1505200 (1)D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares

Explanation of Responses:
(1) These shares are held directly by Frazier Life Sciences Public Fund L.P. The general partner of Frazier Life Sciences Public Fund L.P. is FHMLSP, L.P. and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Frazier Life Sciences Public Fund L.P. FHMLSP, L.P. and FHMLSP, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by Frazier Life Sciences Public Fund L.P., except to the extent of its pecuniary interest therein, if any.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Frazier Life Sciences Public Fund, L.P.
C/O FRAZIER HEALTHCARE PARTNERS
601 UNION STREET, SUITE 3200
SEATTLE, WA 98101

X

FHMLSP, L.P.
C/O FRAZIER HEALTHCARE PARTNERS
601 UNION STREET, SUITE 3200
SEATTLE, WA 98101

X

FHMLSP, L.L.C.
C/O FRAZIER HEALTHCARE PARTNERS
601 UNION STREET, SUITE 3200
SEATTLE, WA 98101

X


Signatures
Frazier Life Sciences Public Fund L.P., By: FHMLSP, L.P., its General Partner. By: FHMLSP, L.L.C., its General Partner, By: /s/ Steve R. Bailey, Chief Financial Officer9/28/2021
**Signature of Reporting PersonDate

FHMLSP, L.P., By: FHMLSP, L.L.C., its General Partner, By: /s/ Steve R. Bailey, Chief Financial Officer9/28/2021
**Signature of Reporting PersonDate

FHMLSP, L.L.C., By: /s/ Steve R. Bailey, Chief Financial Officer9/28/2021
**Signature of Reporting PersonDate

Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Viridian Therapeutics Charts.
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Viridian Therapeutics Charts.